Perspective Therapeutics, Inc. (NYSE:CATX – Get Free Report) CEO Johan M. Spoor purchased 8,000 shares of the firm’s stock in a transaction that occurred on Wednesday, December 4th. The shares were bought at an average price of $3.77 per share, for a total transaction of $30,160.00. Following the acquisition, the chief executive officer now directly owns 36,257 shares in the company, valued at $136,688.89. This trade represents a 28.31 % increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available at this link.
Perspective Therapeutics Stock Performance
NYSE CATX traded down $0.29 during trading hours on Wednesday, hitting $3.71. The company had a trading volume of 1,649,662 shares, compared to its average volume of 849,315. Perspective Therapeutics, Inc. has a 1-year low of $2.28 and a 1-year high of $19.05. The business has a 50 day moving average of $10.27 and a 200-day moving average of $12.15.
Perspective Therapeutics (NYSE:CATX – Get Free Report) last issued its quarterly earnings results on Tuesday, November 12th. The company reported ($0.21) earnings per share for the quarter, hitting the consensus estimate of ($0.21). Perspective Therapeutics had a negative return on equity of 27.40% and a negative net margin of 4,096.66%. The firm had revenue of $0.37 million during the quarter. As a group, analysts expect that Perspective Therapeutics, Inc. will post -0.88 earnings per share for the current year.
Wall Street Analysts Forecast Growth
Check Out Our Latest Analysis on Perspective Therapeutics
Institutional Trading of Perspective Therapeutics
Hedge funds and other institutional investors have recently bought and sold shares of the company. Vanguard Group Inc. increased its holdings in Perspective Therapeutics by 34.6% during the 1st quarter. Vanguard Group Inc. now owns 17,780,106 shares of the company’s stock worth $21,158,000 after purchasing an additional 4,566,356 shares during the last quarter. Virtu Financial LLC bought a new position in shares of Perspective Therapeutics in the first quarter worth $138,000. Bank of New York Mellon Corp boosted its holdings in shares of Perspective Therapeutics by 214.0% in the second quarter. Bank of New York Mellon Corp now owns 137,268 shares of the company’s stock valued at $1,369,000 after acquiring an additional 93,548 shares in the last quarter. Rhumbline Advisers bought a new stake in shares of Perspective Therapeutics in the 2nd quarter worth $630,000. Finally, Victory Capital Management Inc. bought a new position in shares of Perspective Therapeutics during the 2nd quarter valued at about $117,000. 54.66% of the stock is owned by hedge funds and other institutional investors.
About Perspective Therapeutics
Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.
Featured Articles
- Five stocks we like better than Perspective Therapeutics
- Which Wall Street Analysts are the Most Accurate?
- Tesla Poised to Hit Record Highs This Holiday Season
- ESG Stocks, What Investors Should Know
- The Salesforce Rally is Just Getting Started: Here’s Why
- Consumer Staples Stocks, Explained
- 3 Chip and Data Center Stocks That Can Keep Rising in 2025
Receive News & Ratings for Perspective Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Perspective Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.